RenovoRx, Inc. (RNXT)
Delivers chemotherapy directly to pancreatic tumors to improve cancer treatment outcomes.
$0.90-0.07%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-25.9%
The outlook
RNXT trades near the lower end of its 52-week range and shows mixed momentum against its moving averages. Analyst coverage suggests a substantial gap between the current price and average price targets, though investors should note that sparse or speculative coverage can make such targets less reliable. The stock carries a neutral overall rating.
What’s behind the score
Price trendMixed vs its moving averages
52-week range26% of the way from its 52-week low to high
Price targetAvg target +684% vs current price
Analyst price target
~12-month · 4 analysts$7.03average target+683.8% vs now
Now $0.90
Low $3.00High $14.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$40.4M
52-wk high
$1.45
52-wk low
$0.70
50-day avg
$0.90
200-day avg
$0.95
Trailing P/E
—